Publications
14 publications
Funding
1 grant
Active
1 grant- KPKL2TR002385-06Clinical and Translational Science Center - KL2National Center for Advancing Translational Sciences · 2022–2027
Clinical research
4 studies
Active
2 studies- PINCT06179160A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D MutationPHASE1 · Incyte Corporation · OPEN TO ACCRUAL (as of 2026)Solid Tumors
- PIEvaluation of Tumor Microenvironment Modulators Using in Vivo and Ex Vivo Models of Human Gastrointestinal MalignanciesWeill Medical College of Cornell University · OPEN TO ACCRUAL (as of 2024)
Completed & closed trials (2)
- PINCT05673811A Phase IIb, Open-label, Randomized Study of Nab-Paclitaxel and Gemcitabine and Plus/Minus VCN-01 in Patients With Metastatic Pancreatic CancerPHASE2 · Theriva Biologics, Inc. · IRB STUDY CLOSURE (as of 2025)Pancreatic Adenocarcinoma; Metastatic
- PINCT05726864First in Human Phase 1/2 Trial of ELI-002 7P Immunotherapy as Treatment for Subjects With Kirsten Rat Sarcoma (KRAS)/Neuroblastoma RAS Viral Oncogene Homolog (NRAS) Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid TumorsPHASE1; PHASE2 · Elicio Therapeutics, Inc. · CLOSED TO ACCRUAL (as of 2024)Pancreatic Ductal Adenocarcinoma; Colorectal Cancer; KRAS G12D; KRAS G12R; KRAS G12V; KRAS G12A; KRAS G12C; KRAS G12S; KRAS G13D; NRAS G12D; NRAS G12R; NRAS G12V; NRAS G12C; NRAS G12S